Zaeem A. Siddiqi
A5071841592- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Antifungal resistance and susceptibility
- Parkinson's Disease and Spinal Disorders
- Cardiomyopathy and Myosin Studies
- Cancer Treatment and Pharmacology
- Genetic Neurodegenerative Diseases
- Neurological disorders and treatments
- Muscle Physiology and Disorders
- Botulinum Toxin and Related Neurological Disorders
- Alcoholism and Thiamine Deficiency
- Parkinson's Disease Mechanisms and Treatments
- Epilepsy research and treatment
- Long-Term Effects of COVID-19
- Autoimmune Neurological Disorders and Treatments
- Pain Mechanisms and Treatments
- Pharmacological Effects and Toxicity Studies
- Venous Thromboembolism Diagnosis and Management
- Neuroscience and Neuropharmacology Research
- Diet and metabolism studies
- Infectious Encephalopathies and Encephalitis
- Peripheral Nerve Disorders
- Patient-Provider Communication in Healthcare
- Pharmacological Effects of Natural Compounds
- Trigeminal Neuralgia and Treatments
University of Alberta Hospital
2010-2025
University of Alberta
2014-2024
Workers Compensation Board of Alberta
2024
Alberta Hospital Edmonton
2005-2023
Women and Children’s Health Research Institute
2023
Deleted Institution
2021
Novartis (Canada)
2018
Laboratoire de Chimie
2018
Walton Centre
2008
University of Liverpool
2008
<b>Background: </b> This prospective, randomized, double-blind, placebo-controlled, phase III trial assessed the efficacy, safety, and tolerability of mycophenolate mofetil (MMF) as a steroid-sparing agent in patients with myasthenia gravis (MG). <b>Methods: Patients acetylcholine receptor antibody-positive class II-IVa MG (MG Foundation America [MGFA] criteria) taking corticosteroids for at least 4 weeks were randomized to MMF (2 g/day) or placebo 36 weeks. The primary endpoint was...
<h3>Importance</h3> Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to chronic immunosuppression. Therefore, there is a significant need for targeted, well-tolerated therapies the potential improve control enhance quality of life. <h3>Objective</h3> To evaluate zilucoplan, subcutaneously (SC) self-administered macrocyclic peptide inhibitor complement component 5, in broad population...
Significance Our study, involving 1,873 patients and 36,370 healthy individuals, is an extensive genome-wide study of myasthenia gravis. association transcriptome-wide analyses identified two signals, namely CHRNA1 CHRNB1 , encoding acetylcholine receptor subunits, which were replicated in independent cohort obtained from the UK Biobank. Identifying these genes confirms potential utility using genetics to identify proteins that are antigenic targets autoantibodies. We confirmed genetic...
IMPORTANCE-Myasthenia gravis is a chronic, autoimmune, neuromuscular disease characterized by fluctuating weakness of voluntary muscle groups.Although genetic factors are known to play role in this neuroimmunological condition, the etiology underlying myasthenia not well understood.OBJECTIVE-To identify variants that alter susceptibility gravis, we performed genome-wide association study.DESIGN, SETTING, AND PARTICIPANTS-DNA was obtained from 1032 white individuals North America diagnosed as...
We examined the clinical effectiveness of rituximab in fourteen patients with refractory myasthenia gravis (MG). Manual muscle testing (MMT) score was recorded at baseline and followed during course study. Steroid dose, frequency intravenous immunoglobulin (IVIG) infusions, plasma exchange (PLEX) were also monitored throughout duration All responded dramatically to rituximab, as measured by a change MMT score, prednisone or IVIG infusions PLEX. Rituximab appears safe effective for treatment...
<h3>Objective</h3> To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status minimal manifestations (MM), we assessed patients9 throughout REGAIN (Safety and Efficacy Eculizumab in AChR+ Refractory Generalized Gravis) its open-label extension. <h3>Methods</h3> Patients who completed randomized controlled trial continued into...
ABSTRACT Introduction : Rituximab appears to be beneficial in treatment‐refractory myasthenia gravis (MG); however, prospective, long‐term durability data are lacking. Methods In this open‐label study of rituximab refractory MG, 22 patients (10 nicotinic acetylcholine receptor, 9 muscle‐specific tyrosine kinase, 3 seronegative) received at baseline, with repeat cycles driven by clinical worsening. Manual muscle testing (MMT) scores and CD19/CD20 + B‐cell counts were serially monitored....
To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using Quality Life Neurological Disorders (Neuro-QOL) Fatigue subscale, and to correlations between improvements Neuro-QOL other clinical endpoints.Neuro-QOL Fatigue, MG Activities Daily Living (MG-ADL), Quantitative (QMG), 15-item (MG-QOL15) scales were administered during phase 3, randomized, placebo-controlled REGAIN study...
Despite its relative common occurrence, definitive diagnosis of small fiber neuropathy (SFN) remains problematic. In practice, patients with pain, numbness, and/or paresthesias in their lower limbs are diagnosed SFN if found to have dissociated sensory loss feet, that is, impaired pinprick perception (PP) but relatively preserved vibration. We sought assess the sensitivity and specificity clinical examination various diagnostic tools available for screening SFN.Medical records 56 were...
<h3>Objective:</h3> To investigate the efficacy, tolerability, and safety of subcutaneous immunoglobulin (SCIg) in patients with mild to moderate myasthenia gravis (MG) exacerbation. <h3>Methods:</h3> We performed a prospective, open-label, phase 3 trial MG aged 18 years or older worsening (transition from Myasthenia Gravis Foundation America class I II/III II III), treated SCIg (2 g/kg), self-administered over 4 weeks. The primary endpoint was change quantitative (QMG) score baseline study...
Hematopoietic stem cell transplantation (HSCT) may slow the progression of Krabbe disease (KD) if performed early in disease. The authors' studies indicate that more than 90% patients with KD have severe abnormalities peripheral nerve conduction.To assess effect HSCT on conduction KD.The authors serial (NCS) 12 after HSCT. average follow-up was 18 months (6 to 3 years) Pretransplant NCS were not available two patients; all others (10 12) had significant pretransplant abnormalities.After...
Two randomized controlled trials of mycophenolate mofetil (MMF) in the treatment myasthenia gravis (MG) were recently completed. Although neither study demonstrated efficacy MMF population patients studied, there are valuable lessons way these studies developed and performed. After reviewing design results trials, we discuss possible reasons leading to negative learned, which should be useful for future clinical MG.
This study was undertaken to document the effect of age on volume, number, and size neurons in substantia nigra pars compacta (SNpc), paranigral (VTApn), parabrachial pigmentosus (VTApbp) nuclei VTA behaviorally well-characterized rhesus monkeys. Using a point counting technique unbiased stereological methods, we found no significant effects volume these dopaminergic brain stem nuclei, but there age-related loss total number SNpc VTApn. The be greater for measuring less than 200 |xm2 cross...
Krabbe disease (KD) is associated with marked central and peripheral demyelination nerve conduction studies (NCS) typically show a mixed sensorimotor demyelinating neuropathy (PN).To further characterize the PN in large cohort of patients KD to assess diagnostic sensitivity NCS this condition.The authors report results electrodiagnostic performed 27 children KD, ranging age from 1 day 8 years, whose diagnosis was confirmed by leukocyte lysosomal enzyme analysis.Based on age-adjusted...
Abstract Objectives To assess the safety, tolerability, and key pharmacodynamic effects of subcutaneous batoclimab, a fully human anti‐neonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia gravis anti‐acetylcholine antibodies. Methods A Phase 2a, proof‐of‐concept, randomized, double‐blind, placebo‐controlled trial is described. Eligible were randomized (1:1:1) to receive once‐weekly injections batoclimab 340 mg, 680 or matching placebo for 6 weeks. Subsequently,...
This aim of this study was to re-evaluate the types neurons present in pars compacta substantia nigra rhesus monkey, and then determine effects aging on morphology both neuroglial cells. The therefore examined Golgi impregnated material, sections labeled with antibodies tyrosine hydroxylase GABA, tissue embedded plastic for light electron microscopy. Three were encountered: (1) large multipolar prominent Nissl bodies, (2) bipolar that are medium sized spindle-shaped, bodies confined poles...